Nagrestipen

DB12075InvestigationalVaccines

Nagrestipen has been used in trials studying the treatment of CANCER, Neoplasm, Metastasis, Radiation Oncology, and Neoplasm Metastasis.

Mechanism: Pharmacologically active on C-C chemokine receptor type 5, High mobility group protein B1, and C-C chemokine receptor type 1
Curator reviewed
Code names: ECI301

Resolves to

Compound

Targets

What you can answer from here — as of July 07, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Nagrestipen, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.